Imaging peritoneal metastasis of gastric cancer with 18F-fluorothymidine positron emission tomography/computed tomography: a proof-of-concept study
| Autor: | Ken Kato, Yasuhiro Shimada, Tetsuya Hamaguchi, Yasuhide Yamada, Hirokazu Shoji, Atsuo Takashima, Narikazu Boku, Takashi Terauchi, Ukihide Tateishi, Kengo Nagashima, Satoru Iwasa, Daisuke Kano, Yoshitaka Honma |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Fluorine Radioisotopes Lymphatic metastasis Peritoneal metastasis genetic structures Sensitivity and Specificity 030218 nuclear medicine & medical imaging Metastasis Imaging modalities 03 medical and health sciences 0302 clinical medicine Positron Stomach Neoplasms Positron Emission Tomography Computed Tomography medicine Humans Radiology Nuclear Medicine and imaging Peritoneal Neoplasms Aged Positron Emission Tomography-Computed Tomography Full Paper business.industry Cancer General Medicine Middle Aged medicine.disease 18f fluorothymidine Lymphatic Metastasis 030220 oncology & carcinogenesis Female Radiopharmaceuticals business Nuclear medicine Thymidine |
| Zdroj: | The British Journal of Radiology. :20180259 |
| ISSN: | 1748-880X 0007-1285 |
| Popis: | OBJECTIVE: Peritoneal metastasis (PM) is the most frequent form of metastasis in gastric cancer (GC). The sensitivity of detecting PM by pre-operative imaging modalities is low. Utility of positron emission tomography (PET) with (18)F-fluodeoxyglucose (FDG) for GC is limited, because diffuse-type tumors are not FDG-avid. (18)F-fluothymidine ([F-18]FLT) is a radiotracer that reflects cellular proliferation and the utility of [F-18]FLT-PET in GC has been reported. In this proof-of-concept study, we explored the ability of [F-18]FLT-PET/CT to detect PM of GC previously identified by other imaging modalities. METHODS: The key eligibility criteria were as follows; (i) histologically proven gastric adenocarcinoma; (ii) evident PM detected by CT performed within 4 weeks prior to registration; (iii) no prior treatment of PM within 4 weeks before registration. [F-18]FLT-PET/CT was performed at National Cancer Center Hospital, and [F-18]FLT-PET/CT images were evaluated independently by two radiologists. Safety assessments were carried out before and after [F-18]FLT-PET/CT. The primary end point was the detection sensitivity of PM. RESULTS: A total of 19 eligible patients were analyzed, of which 15 (78.9%) had diffuse-type histology. Detection sensitivity of PM, primary lesion, and lymph node metastasis were 73.7% [maximum standardized uptake value (SUVmax): 1.697–13.21], 100% (SUVmax: 2.71–22.01), and 72.7% (SUVmax: 2.079–12.61), respectively. No patients experienced adverse events during or after [F-18]FLT-PET/CT. CONCLUSION: This proof-of-concept study shows that [F-18]FLT-PET/CT is a sensitive method for detecting PM in GC, and paves the way for future studies investigating the clinical utility of this approach for the detection of clinically non-evident PM in GC. ADVANCES IN KNOWLEDGE: This proof-of-concept study found that [F-18]FLT-PET/CT is a sensitive method for detecting peritoneal metastases in GC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|